Tempus AI

Visit Tempus at Booth #1324 to learn more about how Tempus can support your patients across the cancer journey. Hands-on demos are also available for our AI-powered technologies that can streamline your workflow, quickly deliver patient insights, and make precision oncology smarter and more accessible than ever. #SABCS25 Find more information here: https://tempus.co/4iPLEPF

We’re excited to announce that we have received EU IVDR certification for Paige Prostate. This milestone builds on our ongoing work to advance digital pathology while aligning with our commitment to regulatory and quality standards. Paige Prostate is an in vitro software device that supports pathologists in the review of digitized biopsy images, in accordance with its certified intended purpose, and consists of three components: Paige Prostate Detect, Paige Prostate Grade & Quantify, and Paige Prostate Perineural Invasion.

Our late-breaking abstract features newly emerging data accepted for presentation at #SABCS25. This large multimodal #RWD outcome analysis from longitudinal molecular surveillance testing (xF) in HR+/HER2- mBC pts treated with AI+CDK4/6i sheds light on the continuum of ESR1m emergence and patient outcomes from first-line and beyond outside of clinical trial data. Analyses show higher ESR1m incidence is associated with reduced survival regardless of line of therapy. Find more info about the abstract and Tempus at San Antonio Breast Cancer Symposium here: https://tempus.co/4iOZ52g

We’re proud to share that ten abstracts have been accepted for presentation at #SABCS25. This research highlights the power of mulitmodal data in breast cancer care, including the uncovering of specific molecular drivers of progression and resistance. Find presentation times and summaries here: https://tempus.co/4oL50XQ

Join us at #SABCS25 as we showcase our latest clinical research and unveil our most recent cutting-edge, AI-powered technology and product offerings—all designed to drive more informed, personalized care across the cancer journey. Meet the Tempus team at Booth #1324, or learn more here: https://tempus.co/44QbjlB San Antonio Breast Cancer Symposium

We are looking forward to seeing you at #ASH25. Stop by our poster presentation with Robert Huether on Monday, December 8, to learn more about research findings that suggest #WGS is a powerful tool for the comprehensive genomic profiling of leukemia, with potential implications for personalized medicine. Find more info: https://tempus.co/4oABOm4

Join us for an upcoming webinar on Thursday, December 11. Nick Glover, Brad Hirsch, MD, and Matthew Price will join Andy Moye, PhD to discuss practical strategies for integrating real-world data into your company’s decision-making. These biotech and venture capital leaders will share their experiences and discuss how a robust data strategy can inform fundraising and partnership discussions. Register here: https://tempus.co/4oyxXGn

Join Tempus at #ASH25 to see how we’re leveraging our AI-powered technology and real-world data to accelerate research in hematologic malignancies and drive more informed, personalized care across the cancer continuum. Find more info: https://tempus.co/48Br68Z

Healthcare spending in the U.S. is likely to exceed $5.7 trillion and is growing at a pace our economy simply can’t sustain. We’re not just overspending at an epic rate, we're wasting unimaginable sums, with inefficiency and errors driving a large portion of the problem. In my latest blog, I lay out a potential path forward: aligning incentives, accelerating responsible AI adoption, and empowering care teams with tools that prevent mistakes before they happen. https://lnkd.in/gebSRxzt

Our paper, "Translating Deep Learning to Clinical Practice: External Validation and Clinical Benefit of an Electrocardiogram-Based Neural Network for Detecting Low Ejection Fraction" was accepted for presentation at #NeurIPS2025 in San Diego. This research validates our deep learning model for detecting low EF. The model achieved 85.8% sensitivity and 83.0% specificity on an independent validation cohort, with consistent results across demographic subgroups. Read on: https://tempus.co/4iBhcZC